The Generic Drugs Market Size, Share, Growth & Analysis Report 2015 - 2030: Radiant Insights, Inc A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights. Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs. Browse Full Report With TOC @ http://www.radiantinsights.com/research/the-generic-drugsmarket SNS Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets. The “Generic Drugs Market: 2015 – 2030 – Opportunities, Challenges, Strategies & Forecasts” report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries. The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report. Key Findings: The report has the following key findings: - Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years. - As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan. - In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs.
- In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia. - Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020.
Topics Covered: The report covers the following topics: - Generic drugs ecosystem - Market drivers and barriers - Technology, economics and key trends - Pure, branded and super generics Browse Full Report With TOC @ http://www.radiantinsights.com/research/the-generic-drugsmarket - Analysis of key therapeutic areas and leading generic drugs - Regulatory landscape of generic drugs throughout the globe - Industry roadmap and value chain - Profiles and strategies of over 130 leading ecosystem players, including generic and innovator drug manufacturers - Strategic recommendations for ecosystem players - Market analysis and forecasts from 2015 till 2030 Historical Revenue & Forecast Segmentation: Market forecasts are provided for each of the following submarkets and their subcategories: Brand Classification - Pure (Non-branded) Generics - Branded Generics - Super Generics
Therapeutic Area - Antibiotics - Cardiovascular & Hypertension - CNS (Central Nervous System) - Dermatology - Diabetes - Gastrointestinal - Hormonal Drugs - Oncology - Pain Relief - Respiratory - Rheumatology - Others Browse Full Report With TOC @ http://www.radiantinsights.com/research/the-generic-drugsmarket Regional Markets - Asia Pacific - Europe - Middle East & Africa - North America - Latin & Central America Country Markets - Brazil - Canada - China - Egypt
- France - Germany - Greece - India - Israel - Italy - Japan - Mexico Browse Full Report With TOC @ http://www.radiantinsights.com/research/the-generic-drugsmarket - Netherlands - Poland - Portugal - Russia - Saudi Arabia - South Africa - South Korea - Spain - Switzerland - Taiwan - Turkey - UK - USA Key Questions Answered: The report provides answers to the following key questions: - How big is the generic drugs opportunity?
- What trends, challenges and barriers are influencing its growth? - How is the ecosystem evolving by segment and region? - What will the market size be in 2020 and at what rate will it grow? - Which countries and submarkets will see the highest percentage of growth? - How big is the market for generic cancer drugs? - How does regulation impact the adoption of generic drugs? - How will branded and super generics impact revenue prospects? - Who are the key market players and what are their strategies? - How will patent expirations of biologics impact the market? - What are the future prospects of approved and non-approved biosimilar drugs? - What strategies should generic and innovator drug manufacturers adopt to remain competitive? Browse Full Report With TOC @ http://www.radiantinsights.com/research/the-generic-drugsmarket Table of Contents 1
Chapter 1: Introduction 14
1.1
Executive Summary
1.2
Topics Covered 15
1.3
Historical Revenue & Forecast Segmentation
1.4
Key Questions Answered
1.5
Key Findings
19
1.6
Methodology
20
1.7
Target Audience
1.8
Companies & Organizations Mentioned 22
2
Chapter 2: An Overview of Generic Drugs
2.1
What is a Generic Drug?
2.2
Reserve Engineering: How Are Generics Conceived?
14
16
18
21
26
26 26
2.3
The Concept of Bioequivalence: Are Generics the Same as Innovator Drugs?
27
2.3.1
What Defines Bioequivalence? 27
2.3.2
Acceptable Bioequivalence Ranges
2.4
The Question of Brand Quality: Are Generics as Efficient as their Innovator Counterparts? 28
2.5
Economics: Price Comparison 28
2.6
Brand Classification: Pure vs. Branded Generics 29
2.6.1
Pure (Non-branded) Generics
2.6.2
Branded Generics
2.6.3
Super Generics 30
2.7
Market Growth Drivers 31
27
29
29
Browse Full Report With TOC @ http://www.radiantinsights.com/research/the-generic-drugsmarket 2.7.1
Cost Effectiveness and Affordability
2.7.2
Low Insurance Premiums
2.7.3
Patent Expiry of Innovator Drugs
2.7.4
Political & Regulatory Support 32
2.7.5
Global Proliferation & Increasing Demand
2.8
Market Barriers 33
2.8.1
Patent Linkage: Delaying Product Launch
2.8.2
Complex Product Portfolios
2.8.3
Quality Control Issues 33
2.8.4
Intense Competitive Landscape 34
2.8.5
Resistance from Big Pharma Players
34
3
Chapter 3: Regulatory Landscape
35
3.1
Regional Outlook
3.1.1
Asia Pacific
35
35
31
31 31
33
32
33
3.1.2
Europe 37
3.1.3
Middle East & Africa
3.1.4
Latin & Central America
3.1.5
North America 40
3.2
International Initiatives 41
3.2.1
WHO Guidelines
3.2.2
IGDRP (International Generic Drug Regulators Pilot)
3.2.3
EMA (European Medicines Agency): Extending Collaboration beyond the EU
38 39
41 41 42
Browse Full Report With TOC @ http://www.radiantinsights.com/research/the-generic-drugsmarket 4
Chapter 4: Drug Class Availability & Leading Therapies
4.1
Drug Class Availability 43
4.1.1
Antibiotics
4.1.2
Cardiovascular & Hypertension 43
4.1.3
CNS (Central Nervous System) 44
4.1.4
Dermatology
44
4.1.5
Diabetes
45
4.1.6
Gastrointestinal 45
4.1.7
Hormonal Drugs
4.1.8
Onocology
46
4.1.9
Pain Relief
46
4.1.10 Respiratory
47
43
46
4.1.11 Rheumatology 47 4.1.12 Other Categories
47
4.2
Leading Generic Drugs 48
4.2.1
Acetaminophen (Paracetamol) 48
43
4.2.2
Alprazolam
48
4.2.3
Amlodipine
48
4.2.4
Amoxicillin
48
4.2.5
Asprin (Acetylsalicylic Acid)
4.2.6
Atenolol
49
4.2.7
Atorvastatin
49
4.2.8
Azithromycin 49
4.2.9
Bendroflumethiazide
50
4.2.10 Betamethasone Dipropionate 4.2.11 Candesartan
49
50
50
4.2.12 Clavulanic Acid50 4.2.13 Clopidogrel
51
4.2.14 Dexamfetamine 51 Browse Full Report With TOC @ http://www.radiantinsights.com/research/the-generic-drugsmarket 4.2.15 Diclofenac
51
4.2.16 Doxycycline
51
4.2.17 Enalapril
51
4.2.18 Enoxaparin Sodium
52
4.2.19 Esomeprazole 52 4.2.20 Fentanyl
52
4.2.21 Fenofibrate
52
4.2.22 HCTZ (Hydrochlorothiazide) 4.2.23 Ibuprofen
53
4.2.24 Lansoprazole
53
4.2.25 Levothyroxine Sodium 53
52
4.2.26 Lisinopril
53
4.2.27 Losartan
54
4.2.28 Metformin
54
4.2.29 Methylphenidate 4.2.30 Methotrexate
54
4.2.31 Metoprolol
55
4.2.32 Omeprazole
55
54
Browse Full Report With TOC @ http://www.radiantinsights.com/research/the-generic-drugsmarket 4.2.33 Pantoprazole
55
4.2.34 Perindopril
55
4.2.35 Ramipril
56
4.2.36 Rosuvastatin
56
4.2.37 Salbutamol (Albuterol) 56 4.2.38 Simvastatin
56
4.2.39 Valsartan
57
4.2.40 Venlafaxine
57
4.2.41 Others 57 5 Chapter 5: Generic Drugs Industry Roadmap & Value Chain 60 5.1
Industry Roadmap
60
5.1.1
2015 – 2020: Overtaking Innovator Drugs
60
5.1.2
2020 – 2025: The Era of Generic Biologics
61
5.1.3
2025 – 2030 & Beyond: Evolving Regulatory Landscape 61
5.2
Value Chain
5.2.1
API Manufacturers & Enabling Technology Providers
5.2.1
Generic Drug Manufacturers
62
63
62
5.2.2
Innovator Pharmaceutical Companies
63
5.2.3
Regional Distributors
5.2.4
Healthcare Providers, Pharmacies & Drug Stores 64
6
Chapter 6: Key Market Players
6.1
Abbott Laboratories
6.2
AbbVie 66
6.3
ACETO Corporation
6.4
Acino Holding 68
6.5
Actavis 69
6.6
Actelion
6.7
Adcock Ingram 72
64
65
65
67
71
Browse Full Report With TOC @ http://www.radiantinsights.com/research/the-generic-drugsmarket 6.8
Ajinomoto
73
6.9
Akron 74
6.10
Alexion Pharmaceuticals
6.11
Alfa Wasserman
6.12
Amgen 77
6.13
AMRI (Albany Molecular Research, Inc.)
6.14
Amneal Pharmaceuticals
6.15
Apotex 80
6.16
ASKA Pharmaceutical Company
6.17
Aspen Holdings 82
6.18
Astellas Pharma83
6.19
AstraZeneca
6.20
Aurobindo Pharma
75
76
84 85
79
81
78
6.21
Baxter BioScience
86
6.22
Bayer AG
6.23
BD (Becton, Dickinson and Company) 88
6.24
Biogen Idec
6.25
Biocon 90
6.26
Boehringer Ingelheim
6.27
BMS (Bristol-Myers Squibb)
6.28
Cadila Healthcare (Zydus Cadila)
87
89
91 92 93
Browse Full Report With TOC @ http://www.radiantinsights.com/research/the-generic-drugsmarket 6.29
Cadila Pharmaceuticals 94
6.30
Celgene Corporation
95
6.31
Chiesi Farmaceutici
96
6.32
Chugai Pharmaceutical Company
6.33
Claris Lifesciences
6.34
Cipla
6.35
Coherus BioSciences
100
6.36
Consort Medical
101
6.37
Daiichi Sankyo 102
6.38
Dong-A Pharmaceutical 103
6.39
Dr. Reddy's Laboratories
6.40
Eisai Company 105
6.41
Eli Lilly and Company 106
6.42
Endo International
6.43
ESTEVE Group108
6.44
Eurofarma Laboratorios 109
98
99
107
104
97
6.45
Ferring Pharmaceuticals 110
6.46
Fresenius Kabi 111
6.47
Fujifilm Pharma Company
6.48
Fuji Pharma Company 113
6.49
Galderma
114
6.50
Galenika
115
6.51
Gedeon Richter 116
6.52
Genepharm
6.53
Gilead Sciences 118
6.54
Glenmark Pharmaceuticals
112
117
119
Browse Full Report With TOC @ http://www.radiantinsights.com/research/the-generic-drugsmarket 6.55
Grifols 120
6.56
Gruenenthal Group
6.57
GSK (GlaxoSmithKline)
6.58
Hanmi Pharmaceutical Company
6.59
Hetero Drugs
6.60
Hikma Pharmaceuticals 125
6.61
Hospira 126
6.62
Impax Laboratories
6.63
Ipsen
6.64
JT (Japan Tobacco)
129
6.65
Jazz Pharmaceuticals
130
6.66
Johnson & Johnson
131
6.67
Kaken Pharmaceutical Company
6.68
Kaneka Corporation
121 122 123
124
127
128
133
132
6.69
Kowa Company134
6.70
Kremers Urban Pharmaceuticals 135
6.71
Krka (Krka, d. d.)
6.72
Kyowa Hakko Kirin Company 137
6.73
Laboratorios Roemmers 138
6.74
Leo Pharma
6.75
Les Laboratoires Servier
140
6.76
Lundbeck (H. Lundbeck A/S)
141
6.77
Lupin 142
6.78
Mallinckrodt
136
139
143
Browse Full Report With TOC @ http://www.radiantinsights.com/research/the-generic-drugsmarket 6.79
Maruho Company
144
6.80
Meda 145
6.81
Meiji Holdings 146
6.82
Menarini Group 147
6.83
Merck and Co. 148
6.84
Merck KGaA
150
6.85
Merz Pharma
151
6.86
Mitsubishi Tanabe Pharma
6.87
Mitsui & Company
6.88
Mylan 154
6.89
Natco Pharma 155
6.90
Nichi-Iko Pharmaceutical Company
6.91
Nippon Kayaku 157
6.92
Nippon Shinyaku
152
153
158
156
6.93
Nipro Pharma Corporation
159
6.94
Novo Nordisk 160
6.95
Ono Pharmaceutical Company 161
6.96
Orion Corporation
6.97
Otsuka Holdings Company
6.98
Par Pharmaceutical Companies 164
6.99
Perrigo Company
162 163
165
Browse Full Report With TOC @ http://www.radiantinsights.com/research/the-generic-drugsmarket About Radiant Insights Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions. For More Information, Visit Radiant Insights Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Blog URL: http://chemicalmaterialsmarket.blogspot.in/